We examined if ESA exposure could activate signaling pathways by treating viable primary human tumor cell isolates with recombinant human erythropoietin (rHuEpo) and analyzing the effect on the activation state of multiple signaling proteins downstream of cell-surface receptors. This evidence concerns the gene CD177 and neoplasm.